TRAF3, a cytoplasmic adaptor protein, was recently identified as a candidate tumor suppressor in a range of human B-cell lineage neoplasms. Homozygous deletions and inactivating mutations of the Traf3 gene were detected in non-Hodgkin lymphoma, including splenic marginal zone lymphoma (MZL), B-cell chronic lymphocytic leukemia, mantle cell lymphoma, as well as multiple myeloma and Waldenströ m's macroglobulinemia. 1 --4 However, whether TRAF3 deletions or mutations have a causative role in B lymphomagenesis awaits further in vivo study using TRAF3-knockout mice.
We have recently generated a conditional loss-of-function allele of the Traf3 gene that allows specific deletion of TRAF3 in B lymphocytes in mice (B-TRAF3 À/À mice). 5 These mice exhibit greatly expanded B-cell populations in secondary lymphoid organs, due to remarkably prolonged, BAFF-independent survival of mature B cells, a finding subsequently confirmed by Gardam et al. 6 TRAF3 and TRAF2 assemble to form a regulatory complex with cIAP1/2 and NIK to inhibit the NF-kB2-signaling pathway. 7, 8 These observations define a central role of the TRAF3--NIK--NF-kB2 axis in regulating B-cell survival. Prolonged survival of B cells is a known predisposing factor to the development of autoimmunity and B lymphoma. 9, 10 Indeed, aging B-TRAF3 À/À mice developed high levels of serum autoantibodies to double-stranded DNA as well as immune-complex glomerulonephritis. 5 Autoimmunity itself is recognized as a risk factor of B lymphoma in patients with systemic lupus erythematosus or Sjogren's syndrome. 11 Hence, B-TRAF3 À/À mice may be predisposed to B-cell malignancies. Here we report that B-TRAF3 À/À mice spontaneously developed clonal splenic MZL or B1a lymphomas by the age of 18 months.
We first noticed that B-TRAF3
À/À mice have markedly decreased survival rate at ages 49 months ( Figure 1a ). We examined tissues of 50 B-TRAF3
À/À mice 9 --18 months of age, 18 that were necropsied when moribund and 32 that had no external signs of disease at the time of study. All 18 moribund B-TRAF3
À/À mice and 20 out of the other 32 (62.5%) had splenic B lymphoma (Supplementary Table 1 ). Gross observations and microscopic studies also revealed involvement by lymphoma of other tissues including bone marrow, cervical and mesenteric lymph nodes, kidney, lung and liver as well as ascites (Figures 1b and c and Supplementary Figure S1 , and Supplementary Materials and Methods). Based on criteria of the Bethesda classification of lymphoid neoplasms, 12 the tumors of B-TRAF3 À/À mice were splenic MZL, including both high-grade MZL with the cytology of centroblastic diffuse large B-cell lymphomas and low-grade MZL with features of normal MZ B cells.
We next used flow cytometry to characterize the immunophenotypic features of tumor cells present in spleen, bone marrow and ascites (Figure 1d and Supplementary Figure S2 ). Flow cytometric data of 21 individual mice are summarized in Supplementary Table 2 . In keeping with the histologic diagnoses, the immunophenotypic profiles of the tumors were characteristic of mature B-cell lymphomas. With one exception, all tests for canonical mature B-cell markers---B220, CD19, IgM, IgD and Igk or Igl---were positive to varying extents. One exceptional case (27-9) was IgG þ IgM À IgD À with 20% CD138 þ . The immunophenotypic profiles of nine examined lymphomas resembled that of B1a cells whereas two additional cases resembled that of B1b cells. Out of the remaining 10 cases, 5 were CD5 Abbreviations: AA, amino acid; GL, germline sequences; SHM, somatic hypermutation. The IgH VDJ regions of primary TRAF3 À/À B lymphomas were cloned by reverse transcription and PCR using primers V H consensus (5 0 -GTGCAGCTGGTGGAG TCTGG-3 0 ) and C-m4 (5 0 -CCTGGATGACTTCAGTGTTGTTCTG-3 0 ). The high-fidelity polymerase, Pfu UltraII, was used in the amplification reaction. PCR products were subsequently subcloned into pBlueScript vector. Mini-prep DNAs of about 20 clones of each B-lymphoma sample were sequenced using the primer C-mSq (5 0 -CCA-CCA-GAT-TCT-TAT-CAG-ACA-GGG-3 0 ). À/À B-lymphoma cells purified from B-TRAF3 À/À mice were treated without (CTL) or with 0.5 mM BMS-345541 (BMS) or 2 mg/ml oridonin. Cytosolic and nuclear extracts were prepared at indicated time points (3 or 6 h) after treatment, and then immunoblotted for NF-kB2 (p100---p52), RelB, NF-kB1 (p50), RelA, c-Rel and PKCd. Immunoblots of actin and HDAC1 were used as loading control for cytosolic and nuclear proteins, respectively. Data are representative of three independent experiments. the same mice often exhibited rearranged bands of similar size, indicating metastatic spread of the same clone.
These observations prompted us to seek more direct evidence for malignant transformation by intraperitoneal transfer of tumor cells with known clonal populations to immunodeficient NOD SCID mice. At 2 --3 months after transfer, recipient mice were found to have lymphoma infiltrates in multiple tissues. The transplanted tumors had the same immunophenotypic features as the donor population (Figure 1f) . Southern blot analyses revealed that one or two clonal populations from primary TRAF3 À/À B lymphomas were propagated in NOD SCID recipient mice (Figure 1g) . Thus, the spontaneous B lymphomas that developed in B-TRAF3 À/À mice are clonal, malignant and transplantable.
To gain additional information about the origin, partitioning and history of malignant B cells, we cloned and sequenced the IgH Letters to the Editor V(D)J regions of lymphomas from 11 B-TRAF3 À/À mice ( Table 1 ). The IgH V region sequences of 10 of the 11 examined mice did not exhibit significant somatic hypermutation, suggesting that they were not derived from germinal center-passaged cells but rather from naive pre-germinal center B cells, MZ B cells or B1 cells. Interestingly, all of the major V H sequences identified in TRAF3 À/À B lymphomas belonged to one of four V H families, VH1 (J558), VH3 (VH36-60), VH5 (VH7183) and VH12. These gene families are frequently used by MZ, B1, or autoreactive B cells. Thus, IgH V(D)J sequences, together with the histopathological and immunophenotypic data, allow us to classify B lymphomas developed in most B-TRAF3 À/À mice as splenic MZL or B1 lymphomas. We previously showed constitutive activation of NF-kB2 and decreased nuclear translocation of PKCd, but normal CD40-induced NF-kB1 activation in premalignant TRAF3 À/À B cells. 5 Here, we extended our analyses of these pathways to lymphomas of B-TRAF3 À/À mice. We found that the elevated nuclear levels of the NF-kB2 subunits, p52 and RelB, and the decreased nuclear levels of PKCd were also features of primary B lymphomas (Figure 2a) . Interestingly, TRAF3
À/À B lymphomas also had moderately increased nuclear levels of the NF-kB1. Hence, the signaling landscape of TRAF3 À/À B lymphomas is characterized by constitutive activation of both the NF-kB2 and NF-kB1 (albeit to a lesser extent) pathways as well as reduced nuclear translocation of PKCd.
To test whether aberrant NF-kB activation pathways could serve as therapeutic targets for B-cell neoplasms associated with TRAF3 inactivation, we evaluated the effects on cell viability of drugs that modulate NF-kB activation using primary B-lymphoma cells purified from B-TRAF3 À/À mice. We used an inhibitor of IKK2, BMS-345541, 13 and an inhibitor of NF-kB, oridonin. 14 The effects of these agents were compared with the activities of drugs used clinically to treat B lymphomas or leukemias---vincristine, all trans-retinoic acid, doxorubicin and cyclophosphamide. We found that oridonin exhibited potent dose-dependent tumoricidal activity on primary lymphoma cells, whereas BMS-345541 and the four clinical drugs were inactive (Figures 2b and c and Supplementary Figure S3) .
To understand the mechanisms of oridonin, we determined the levels of NF-kB2 and NF-kB1 subunits in cytosolic and nuclear extracts of primary B lymphomas. The levels of activated NF-kB2 and NF-kB1 in the nucleus were markedly reduced in B lymphoma cells treated with oridonin (Figure 2d) . Furthermore, nuclear translocation of PKCd, or activation of ERK, p38, JNK, and AKT was unaffected by oridonin (Figure 2d and data not shown) . Thus, the potent tumoricidal effects of oridonin can be ascribed to its activity in inhibiting the activation of both NF-kB2 and NF-kB1, suggesting that oridonin or closely related agents should be considered as new candidates for the treatment of B-cell neoplasms characterized by genetic/epigenetic inactivation of TRAF3.
We next sought to specifically decrease the NF-kB2 level using lentiviral shRNA vectors to evaluate the role of constitutive NF-kB2 activation in TRAF3 À/À B lymphomagenesis. We screened 4 NF-kB2 shRNA lentiviral vectors. The NF-kB2 shRNA 653 and 1226 knocked down both p100 and p52 NF-kB2 proteins to B95% and B75% reduction, respectively. We subsequently used these shRNA lentiviruses to transduce the TRAF3 À/À B-lymphoma cell line 27-9.5.3 generated in this study (Supplementary Materials and Methods). Interestingly, both NF-kB2 shRNA 653 and 1226 inhibited the proliferation and induced apoptosis in 27-9.5.3 cells. Importantly, the potency of the two shRNAs in knocking down NF-kB2 protein levels correlated with their ability in inhibiting the proliferation and inducing apoptosis in TRAF3 À/À B-lymphoma cells ( Figure 3 ). Although confirmation using additional TRAF3
À/À B-lymphoma lines is necessary, our data suggest that constitutive NF-kB2 activation is one major oncogenic pathway in TRAF3 À/À B cells. Studies that identified TRAF3 deletions and mutations in B-cell chronic lymphocytic leukemia, MZL, mantle cell lymphoma, Waldenströ m's macroglobulinemia and multiple myeloma suggest potential tumor-suppressive function of TRAF3. 1 --4 Paradoxically, transgenic mice overexpressing TRAF3 in B cells display autoimmune disease, systemic inflammation and are predisposed to Letters to the Editor cancers. 15 One possibility raised by Zapata et al. 15 is that TRAF3 may promote plasma cell differentiation. Alternatively, the unexpected phenotype of TRAF3-transgenic mice may potentially relate to the site of transgene insertion in the genome that may affect the expression or function of additional important gene(s), considering that only a single transgenic founder line was examined in detail. 15 Here, the spontaneous, highly penetrant development of B lymphomas in B-TRAF3 À/À mice provides conclusive evidence that Traf3 is a tumor-suppressor gene in B cells.
Collectively, data presented in the present study indicate that B-TRAF3 À/À mice closely model human splenic MZL and B-cell chronic lymphocytic leukemia. Using B lymphoma cells derived from B-TRAF3 À/À mice as model systems, we demonstrated that oridonin and NF-kB2 shRNAs have therapeutic potential. Our findings suggest that restoration of TRAF3 protein or its downstream signaling pathways represents important therapeutic avenues of B lymphomas. In this context, B-TRAF3 À/À mice provide a useful tool for developing and testing therapeutic drugs for the treatment of human B-cell neoplasms involving TRAF3 inactivation or relevant genetic/epigenetic alterations.
